Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy NextCure  stock

Learn how to easily invest in NextCure  stock.

NextCure  is a biotechnology business based in the US. NextCure  shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. NextCure  employs 87 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy NextCure  stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – NXTC. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

NextCure  stock price (NASDAQ: NXTC)

Use our graph to track the performance of NXTC stocks over time.

NextCure  shares at a glance

Information last updated 2023-02-02.
Latest market close$1.63
52-week range$1.16 - $5.54
50-day moving average $1.48
200-day moving average $3.23
Wall St. target price$5.25
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.66

Buy NextCure  stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy NextCure  stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NextCure  price performance over time

Historical closes compared with the close of $1.63 from 2023-02-01

1 week (2023-01-26) 1.24%
1 month (2022-12-30) 15.60%
3 months (2022-11-02) -34.01%
6 months (2022-08-02) -62.00%
1 year (2022-02-01) -71.30%
2 years (2021-02-02) -86.66%
3 years (2020-01-31) 42.75
5 years (2018-01-29) N/A

NextCure  financials

Gross profit TTM $-4,081,000
Return on assets TTM -21%
Return on equity TTM -34.61%
Profit margin 0%
Book value $6.54
Market capitalisation $45.3 million

TTM: trailing 12 months

NextCure  share dividends

We're not expecting NextCure  to pay a dividend over the next 12 months.

NextCure  share price volatility

Over the last 12 months, NextCure 's shares have ranged in value from as little as $1.16 up to $5.54. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NextCure 's is -0.0234. This would suggest that NextCure 's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NextCure  has bucked the trend.

NextCure  overview

NextCure, Inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc.

Frequently asked questions

What percentage of NextCure  is owned by insiders or institutions?
Currently 8.758% of NextCure  shares are held by insiders and 62.263% by institutions.
How many people work for NextCure ?
Latest data suggests 87 work at NextCure .
When does the fiscal year end for NextCure ?
NextCure 's fiscal year ends in December.
Where is NextCure  based?
NextCure 's address is: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705
What is NextCure 's ISIN number?
NextCure 's international securities identification number is: US65343E1082
What is NextCure 's CUSIP number?
NextCure 's Committee on Uniform Securities Identification Procedures number is: 65343E108

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site